Recursion Pharmaceuticals annual operating margin
2019
2020
2021
2022
2023
2024
2025
Recursion Pharmaceuticals's operating margin was −867.87% for fiscal 2025.
View full Recursion Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −867.87% | −53.77 pp |
| 2024 | 2024-12-31 | −814.09% | −28.76 pp |
| 2023 | 2023-12-31 | −785.33% | −168.59 pp |
| 2022 | 2022-12-31 | −616.74% | +1179.05 pp |
| 2021 | 2021-12-31 | −1,795.79% | +339.88 pp |
| 2020 | 2020-12-31 | −2,135.66% | +556.92 pp |
| 2019 | 2019-12-31 | −2,692.58% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,759.69% | −842.94 pp |
| Q1 2026 | 2026-03-31 | −1,985.55% | −687.70 pp |
| Q4 2025 | 2025-12-31 | −304.84% | +3737.55 pp |
| Q3 2025 | 2025-09-30 | −3,327.57% | −2950.48 pp |
| Q2 2025 | 2025-06-30 | −916.75% | −219.36 pp |
| Q1 2025 | 2025-03-31 | −1,297.85% | −599.43 pp |
| Q4 2024 | 2024-12-31 | −4,042.39% | −3134.02 pp |
| Q3 2024 | 2024-09-30 | −377.10% | +568.03 pp |
| Q2 2024 | 2024-06-30 | −697.39% | +44.33 pp |
| Q1 2024 | 2024-03-31 | −698.42% | −122.64 pp |
| Q4 2023 | 2023-12-31 | −908.36% | −462.46 pp |
| Q3 2023 | 2023-09-30 | −945.12% | −469.65 pp |
| Q2 2023 | 2023-06-30 | −741.72% | +120.82 pp |
| Q1 2023 | 2023-03-31 | −575.78% | +473.93 pp |
| Q4 2022 | 2022-12-31 | −445.91% | +2118.64 pp |
| Q3 2022 | 2022-09-30 | −475.48% | +1355.70 pp |
| Q2 2022 | 2022-06-30 | −862.54% | +743.15 pp |
| Q1 2022 | 2022-03-31 | −1,049.71% | +140.14 pp |
| Q4 2021 | 2021-12-31 | −2,564.55% | −1613.93 pp |
| Q3 2021 | 2021-09-30 | −1,831.18% | +361.41 pp |
| Q2 2021 | 2021-06-30 | −1,605.69% | +8188.40 pp |
| Q1 2021 | 2021-03-31 | −1,189.85% | +29381.81 pp |
| Q4 2020 | 2020-12-31 | −950.61% | — |
| Q3 2020 | 2020-09-30 | −2,192.59% | — |
| Q2 2020 | 2020-06-30 | −9,794.09% | — |
| Q1 2020 | 2020-03-31 | −30,571.67% | — |
Over the last five reported fiscal years, Recursion Pharmaceuticals's operating margin increased from −2,135.66% to −867.87%, a change of +1267.80 percentage points. The latest reported quarter, Q2 2026, shows −1,759.69%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals filings at SEC.gov ↗